z-logo
Premium
Chemically Programmable and Switchable CAR‐T Therapy
Author(s) -
Qi Junpeng,
Tsuji Kohei,
Hymel David,
Burke Terrence R.,
Hudecek Michael,
Rader Christoph,
Peng Haiyong
Publication year - 2020
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.202005432
Subject(s) - biodistribution , chimeric antigen receptor , small molecule , in vitro , antibody , in vivo , chemistry , antigen , receptor , immune system , biophysics , microbiology and biotechnology , biochemistry , t cell , biology , immunology , genetics
Although macromolecules on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small molecules and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility. Compared to antibodies, however, small molecules are disadvantaged by a less confined biodistribution, shorter circulatory half‐life, and inability to communicate with the immune system. Presented herein is a method that endows small molecules with the ability to recruit and activate chimeric antigen receptor T cells (CAR‐Ts). It is based on a CAR‐T platform that uses a chemically programmed antibody fragment (cp‐Fab) as on/off switch. In proof‐of‐concept studies, this cp‐Fab/CAR‐T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate‐receptor‐expressing cancer cells in vitro and in vivo.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here